The increased risk of local and distant disease recurrence in these groups is independently calculated as HR 2.93 (CI 1.43-5.98 p = 0.003) for tumour size designated T2, HR 4.24 (CI 1.78-10.11 p < 0.001) for T3-4, HR 4.47 (CI 1.92-10.38 p < 0.001) and HR 5.8 (CI 2.53-13.31 p < 0.001) for N stages 2 and 3 respectively and HR 3.7 (CI 1.14-12.05 p = 0.03) for subtype ER-, HER2-. This evidence concerns the gene ERBB2 and neoplasm.